Feature · DeepSensi PBC, Dover, Delaware · July 2026 · press@deepsensi.com
There is a way to describe DeepSensi that is accurate and completely misses the point. You can call it a diagnostic AI — it reasons through the hardest cases in medicine at the level of a university consilium. You can call it a clinical documentation tool, a physician-reputation system, a trial-matching service, an epidemic-surveillance layer, a safety-certification standard. Each is true. Each, on its own, describes a product. Together they describe something for which the industry does not yet have the right word, and using the wrong word — "another medical AI" — is how serious people underestimate what has actually been built.
The founder, Tomasz Jan Gomoła, reaches for a different image, and it is the right one. Think of a physician putting on armor. Not a lab coat — a medical exosuit. Alone, a doctor at 3 a.m. is one tired human being with one memory, one training, one pair of hands. Put on the DeepSensi exosuit and that same doctor is suddenly moving with the power of an entire teaching hospital: a full bench of specialists deliberating every case, a research library that checks each claim before it is spoken, a scribe that writes the note, a memory that never forgets a patient, a pharmacist that catches the fatal interaction. The physician is still the one who decides, still the one who signs. But the reach of that signature is now institutional. Every doctor wearing the exosuit commands the resources it used to take a hospital to assemble.
The distinction that matters is the one between an application and an operating system. The last decade of health technology delivered applications: a sepsis alert here, an imaging classifier there, a scribe, a chatbot, a risk score. Each solved a slice. None of them held the patient. They ran side by side without a shared substrate, a shared memory, or a shared standard of proof, which is why so many of them stalled at the pilot stage — clever demonstrations that never became infrastructure.
An operating system is different in kind. It is the layer everything else runs on, and its value is not any single function but the fact that every function inherits the same guarantees. In DeepSensi, the diagnosis, the documentation, the memory, the trial match, and the epidemic signal all pass through the same verification cascade, are all sealed into the same court-grade audit trail, and are all bounded by the same published error mathematics. The diagnostic engine is not a feature of the platform; it is a service the whole platform calls. So is the memory that alerts a physician years after a visit when new science changes a patient's picture. So is the radar that reads the de-identified exhaust of ordinary documentation to see an outbreak forming. That is what an operating system for medicine looks like: not a smarter app, but the ground the apps stand on.
New categories are usually claimed and rarely earned. What separates a genuine category from a marketing slogan is whether it comes with a standard — a way for anyone to tell the real thing from the impostor. DeepSensi's answer is unusual: it published the test and gave it away. The DeepSensi Standard is an open, royalty-free certification for the safety of clinical AI, with explicit, quantitative error bounds any regulator or competitor may adopt. It is the company effectively saying: here is the bar for this category, including a bar we must clear ourselves, and we will not hide the ruler. A category defined by an open standard is far harder to fake than one defined by a demo, and far more valuable to be the origin of.
It would have been easy — and, commercially, tempting — to build this as a consumer novelty and let the marketing outrun the mathematics. DeepSensi went the other way. It measures its error rate the way aviation and nuclear engineering measure theirs. It publishes an honest "I don't know" as a first-class clinical output instead of manufacturing false confidence. It refuses to claim results it has not earned, stating plainly in its own papers where an evaluation is still prospective. It writes free trial-matching for patients into its charter as a hard constraint no future business decision can revoke. These are not the choices of a company building a feature. They are the choices of a company that believes it is building infrastructure that other people's lives will run on — and is behaving accordingly.
That is the frame that does the system justice. Not an app that got smarter. A new layer under medicine — one that gives every physician the power of a hospital, remembers every patient, watches over a population's health, and submits itself to a standard it published for the world to check. The industry will need a name for that. "Medical AI" is not it.
Technical documentation: www.deepsensi.com/papers · Press and interviews: press@deepsensi.com · DeepSensi PBC is a Public Benefit Corporation.